NEW YORK (GenomeWeb) — Illumina has partnered with AstraZeneca, Janssen Biotech, and Sanofi to develop a universal next-generation sequencing-based oncology test system for multi-analyte companion diagnostics, the company said today.

The goal of the partnership is to transition from single-analyte companion diagnostics to panel-based assays to select cancer therapies for patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.